BridgeBio Oncology Therapeutics, Inc. BBOT
Set alert
2.62 USD -0.08 -2.96%
At close · Oct 30
2.62 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
2.61 Day range 2.74
2.62 52-week range 13.73
- YTD
- -79.07%
- 1 year
- -78.17%
- Open
- 2.70
- Prev close
- 2.70
- Mkt cap
- 210.06M
- Vol
- 314.79K
- Avg vol
- 540.08K
- EPS
- -0.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.61
- High
- 2.74
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 4.43
- Inst. own
- 52.88%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 11.45
- 200-d avg
- 10.84
- 1y target
- 24.20
Financial health
Altman Z-Score
-0.44 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
0 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 5
Valuation
P/E -2.9×
FY 2021 5y median -4852× FY 2025
P/S 0.0×
FY 2021 5y median 0.0× FY 2025
P/B 0.9×
FY 2021 5y median -3284× FY 2025
P/FCF -3.4×
FY 2021 5y median -0.2× FY 2025
EV/EBITDA -0.1×
FY 2021 5y median -0.1× FY 2025
EV/Sales 0.0×
FY 2021 5y median 0.0× FY 2025
FCF Yield -29.4%
FY 2021 5y median -25.1% FY 2025
Profitability
Gross Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2021 5y median 0.0% FY 2025
ROE -32.6%
FY 2021 5y median 16.1% FY 2025
ROIC -35.2%
FY 2021 5y median -41.6% FY 2025
ROA -29.9%
FY 2021 5y median -30.1% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income -80.3%
FY 2021 FY 2025
EPS (diluted) 99.9%
FY 2021 FY 2025
Free Cash Flow -14890.4%
FY 2021 FY 2025
Financial Health
Current Ratio 12.1×
FY 2021 5y median 0.0× FY 2025
Quick Ratio 12.1×
FY 2021 5y median 0.0× FY 2025
Debt / Equity 0.0×
FY 2021 5y median -1.1× FY 2025
Net Debt / EBITDA 2.6×
FY 2021 5y median 0.0× FY 2025
Interest Coverage 0.0×
FY 2021 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31